This is a regulatory disclosure submitted to BSE Limited and the National Stock Exchange of India Limited under Regulation 30 of the SEBI LODR Regulations, 2015. It details the outcomes of the Board of Directors meeting held on August 22, 2026.

Key Resolutions Approved:

1. 19th Annual General Meeting (AGM) and Annual Report

  • The Board approved the notice convening the 19th AGM of the Company.
  • The AGM is scheduled to be held on Thursday, September 24, 2026, at 11:30 a.m. (IST) through video conferencing/other audio-visual means.
  • The notice and the Annual Report for the financial year 2025-26 will be dispatched to shareholders and intimated to the stock exchanges within statutory timelines.
  • The Board also considered and adopted the Annual Report for FY 2025-26.

2. Re-appointment and Remuneration of Mr. Ram Mohan Lokhande

  • The Board approved the re-appointment of Mr. Ram Mohan Lokhande (DIN: 08117035) as a Whole-Time Director.
  • His new term is for five consecutive years, effective from February 08, 2027, to February 07, 2032.
  • His current tenure is set to expire on February 07, 2027.
  • The approval for his remuneration was also granted.
  • This re-appointment is based on the recommendation of the Nomination and Remuneration Committee and is subject to the approval of shareholders at the ensuing 19th AGM.
  • Brief Profile: Mr. Lokhande holds a Doctorate in Applied Psychology and an Executive MBA from SP Jain Institute of Management & Research, Mumbai. He is a seasoned pharmaceutical professional with extensive experience in Active Pharmaceutical Ingredients (API) and specialty chemicals manufacturing. His expertise includes strategic planning, cost controls, risk mitigation, production planning, and quality systems.
  • He is not related to any other Directors or Key Managerial Personnel (KMP) of the Company and is not debarred from holding the office of director by any SEBI or other authority order.

3. Re-appointment of Mrs. Anita Bandyopadhyay

  • The Board approved the re-appointment of Mrs. Anita Bandyopadhyay (DIN: 08672071) as a Non-Executive & Independent Director.
  • This is her second term, also for five consecutive years, effective from February 08, 2027, to February 07, 2032.
  • Her current tenure is set to expire on February 07, 2027.
  • The re-appointment is based on the recommendation of the Nomination and Remuneration Committee and is subject to the approval of shareholders at the ensuing 19th AGM.
  • Brief Profile: Mrs. Bandyopadhyay is a B.Tech in Chemical Engineering from the National Institute of Technology, Warangal. She is the Founder Director of Kafe HR and a distinguished Human Resources professional. Her expertise includes strategic human resource management, leadership development, talent management, performance management systems, organizational design, and corporate succession planning.
  • She is not related to any other Directors or KMP of the Company and is not debarred from holding the office of director by any SEBI or other authority order.

4. Extension of ESOS 2023 to Subsidiary Employees

  • The Board approved a proposal to extend the benefits of the Ami Organics Employees Stock Option Scheme 2023 (ESOS 2023) to eligible employees of the Company's Indian subsidiary(ies).
  • This approval is based on the recommendation of the Nomination and Remuneration Committee and is subject to the approval of shareholders at the ensuing 19th AGM.

5. Capital Expenditure Plan

  • The Board approved a capital expenditure plan with a total financial outlay of up to ₹212 crores (Rupees Two Hundred and Twelve Crores only).
  • The purpose of the capex is for the establishment of a greenfield/brownfield manufacturing plant in the state of Gujarat for new electronic grade chemicals.
  • The project may be undertaken either by the Company itself or through any of its subsidiary companies.
  • Project Details (From Annexure B):
  • Existing Capacity: NIL for the proposed new electronic grade chemicals.
  • Existing Capacity Utilisation: NIL for the proposed new electronic grade chemicals.
  • Proposed Capacity: Up to 81,000 MT per annum.
  • Implementation Timeline: The proposed capacity is to be added by the end of FY 2027-28.
  • Mode of Financing: Through internal accruals of the Company and/or bank finances or other permissible methods.
  • Rationale: To establish a manufacturing facility for new electronic grade chemicals.